Loss of Heterozygosity (LOH), Malignancy Grade and Clonality in Microdissected Prostate Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Feb 23

PMID 10027329

Citations 13

Authors

A HUGEL

N Wernert

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to find out whether increasing malignancy of prostate carcinoma correlates with an overall increase of loss of heterozygosity (LOH), and whether LOH typing of microdissected tumour areas can help to distinguish between multifocal or clonal tumour development. In 47 carcinomas analysed at 25 chromosomal loci, the overall LOH rate was found to be significantly lower in grade 1 areas (2.2%) compared with grade 2 (9.4%) and grade 3 areas (8.3%, P = 0.007). A similar tendency was found for the mean fractional allele loss (FAL, 0.043 for grade 1, 0.2 for grade 2 and 0.23 for grade 3, P = 0.0004). Of 20 tumours (65%) with LOH in several microdissected areas, 13 had identical losses at 1-4 loci within two or three areas, suggesting clonal development of these areas. Markers near RB, DCC, BBC1, TP53 and at D13S325 (13q21-22) showed higher loss rates in grades 2 and 3 (between 25% and 44.4%) compared with grade 1 (0-6.6%). Tumour-suppressor genes (TSGs) near these loci might, thus, be important for tumour progression. TP53 mutations were detected in 27%, but BBC1 mutations in only 7%, of samples with LOH. Evaluation of all 25 loci in every tumour made evident that each prostate cancer has its own pattern of allelic losses.

Citing Articles

All who wander are not lost: the search for homology during homologous recombination.

Hu J, Crickard J Biochem Soc Trans. 2024; 52(1):367-377.

PMID: 38323621 PMC: 10903458. DOI: 10.1042/BST20230705.

Rad53 regulates the lifetime of Rdh54 at homologous recombination intermediates.

Hu J, Ferlez B, Dau J, Crickard J Nucleic Acids Res. 2023; 51(21):11688-11705.

PMID: 37850655 PMC: 10681728. DOI: 10.1093/nar/gkad848.

Epigenetics in prostate cancer treatment.

Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C J Transl Genet Genom. 2022; 5:341-356.

PMID: 35372800 PMC: 8974353. DOI: 10.20517/jtgg.2021.19.

Clonal origin and spread of metastatic prostate cancer.

Van Etten J, Dehm S Endocr Relat Cancer. 2016; 23(4):R207-17.

PMID: 27000662 PMC: 4895916. DOI: 10.1530/ERC-16-0049.

Tumor focality in prostate cancer: implications for focal therapy.

Karavitakis M, Ahmed H, Abel P, Hazell S, Winkler M Nat Rev Clin Oncol. 2010; 8(1):48-55.

PMID: 21116296 DOI: 10.1038/nrclinonc.2010.190.

References

Moul J, Friedrichs P, Lance R, Theune S, Chang E . Infrequent RAS oncogene mutations in human prostate cancer. Prostate. 1992; 20(4):327-38. DOI: 10.1002/pros.2990200407. View

Gumerlock P, Poonamallee U, Meyers F, deVere White R . Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 1991; 51(6):1632-7. View

Gao X, Honn K, Grignon D, Sakr W, Chen Y . Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res. 1993; 53(12):2723-7. View

Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R . Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol. 1993; 150(1):126-31. DOI: 10.1016/s0022-5347(17)35413-7. View

Kuhn E, Kurnot R, Sesterhenn I, Chang E, Moul J . Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol. 1993; 150(5 Pt 1):1427-33. DOI: 10.1016/s0022-5347(17)35799-3. View

Deimling A, Bender B, Louis D, Wiestler O . A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol. 1993; 19(6):524-9. DOI: 10.1111/j.1365-2990.1993.tb00481.x. View

Bender B, Wiestler O, Deimling A . A device for processing large acrylamide gels. Biotechniques. 1994; 16(2):204-6. View

Trapman J, Sleddens H, Van der Weiden M, Dinjens W, Konig J, Schroder F . Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res. 1994; 54(23):6061-4. View

Zenklusen J, Thompson J, Troncoso P, Kagan J, Conti C . Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res. 1994; 54(24):6370-3. View

10.

Bookstein R . Tumor suppressor genes in prostatic oncogenesis. J Cell Biochem Suppl. 1994; 19:217-23. View

11.

Gao X, Zacharek A, Salkowski A, Grignon D, Sakr W, Porter A . Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res. 1995; 55(5):1002-5. View

12.

Konishi N, Hiasa Y, Matsuda H, Tao M, Tsuzuki T, Hayashi I . Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol. 1995; 147(4):1112-22. PMC: 1871010. View

13.

Helps N, Adams S, Brammar W, Varley J . The Drosophila melanogaster homologue of the human BBC1 gene is highly expressed during embryogenesis. Gene. 1995; 162(2):245-8. DOI: 10.1016/0378-1119(95)00356-b. View

14.

Macoska J, Trybus T, Benson P, Sakr W, Grignon D, Wojno K . Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 1995; 55(22):5390-5. View

15.

Lin J, Wu X, Chen J, Chang A, Levine A . Functions of the p53 protein in growth regulation and tumor suppression. Cold Spring Harb Symp Quant Biol. 1994; 59:215-23. DOI: 10.1101/sqb.1994.059.01.026. View

16.

Vocke C, Pozzatti R, Bostwick D, Florence C, Jennings S, Strup S . Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 1996; 56(10):2411-6. View

17.

Isaacs W . Molecular genetics of prostate cancer. Cancer Surv. 1995; 25:357-79. View

18.

Cunningham J, Shan A, Wick M, McDonnell S, Schaid D, Tester D . Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res. 1996; 56(19):4475-82. View

19.

Latil A, Fournier G, Cussenot O, Lidereau R . Differential chromosome allelic imbalance in the progression of human prostate cancer. J Urol. 1996; 156(6):2079-83. View

20.

Hanash K, Utz D, COOK E, Taylor W, TITUS J . Carcinoma of the prostate: a 15-year followup. J Urol. 1972; 107(3):450-3. DOI: 10.1016/s0022-5347(17)61053-x. View